Skip to main content

Market Overview

FDA OKs Apple Watch To Help Monitor Symptoms Of Parkinson's Disease

Share:
FDA OKs Apple Watch To Help Monitor Symptoms Of Parkinson's Disease

A San Francisco-based software company received permission from the U.S. Food and Drug Administration to use Apple Inc. (NASDAQ: AAPL) wearable technology to track Parkinson's symptoms.

Rune Labs' StrivePD software "draws data directly from Apple's Movement Disorder API, which provides a power-efficient approach to measuring and recording tremors and dyskinetic symptoms common in patients with Parkinson's disease," the company explained in a prepared statement.

Related Link: This Third-Party Apple Watch Strap Lets You Measure Body Fat And Water Level

The StrivePD app would be the first significant use of Apple's software tools to measure movement disorders since the features were released in 2018, Reuters reported. Last year, Apple published data illustrating how its watch could track motor symptoms of patients with Parkinson’s disease.

The Apple Watch's success as a data-capturing device depends on whether FDA-grade accuracy is ensured across the spectrum of Watch's features, according to Loup Ventures analyst Gene Munster.

Apple closed Monday's session 3.83% lower at $131.88, according to Benzinga Pro data.

Separately, Rune Labs has also partnered with Medtronic plc (NYSE: MDT) to understand the effects of neurostimulation in order to improve patient care.

 

Related Articles (AAPL)

View Comments and Join the Discussion!

Posted-In: Consumer Tech Parkinson'sNews Health Care FDA Tech General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com